NeuroPace
Developing and marketing implantable devices for the treatment of neurological disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 9.0x EV/Revenue -29.6x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $75.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 10 % | 1 % | 44 % | 22 % | 20 % | 7 % | 27 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63 %) | (87 %) | (35 %) | (21 %) | (14 %) | (8 %) | 3 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (80 %) | (103 %) | (50 %) | (34 %) | (28 %) | (18 %) | (6 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 40 % | 48 % | 32 % | 30 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
NeuroPace is a medical device company that has developed a brain-responsive neuromodulation system for treating epilepsy. This system, known as the RNS System, is designed to monitor and respond to a patient's brain activity to prevent seizures. The company's primary market is individuals with refractory epilepsy, a form of the condition that does not respond to medication.
The RNS System is an implantable device that provides personalized treatment by delivering electrical stimulation to the brain when it detects abnormal activity. This approach is intended to reduce the frequency and severity of seizures, improving the quality of life for patients. The company operates on a business model that involves the sale of these devices to healthcare facilities and providing ongoing support and data analysis services.
NeuroPace is a publicly traded company, and its revenue is generated through the sale of the RNS System and related components. The company is focused on expanding the adoption of its technology and continuing to develop its platform for other neurological disorders.
Keywords: medical devices, neuromodulation, epilepsy treatment, implantable devices, neurostimulation, brain-computer interface, personalized medicine, seizure prevention, refractory epilepsy, neurological disorders